PE20190260A1 - Isoquinolin-3-il-carboxamidas, y preparacion y uso de las mismas - Google Patents

Isoquinolin-3-il-carboxamidas, y preparacion y uso de las mismas

Info

Publication number
PE20190260A1
PE20190260A1 PE2018002175A PE2018002175A PE20190260A1 PE 20190260 A1 PE20190260 A1 PE 20190260A1 PE 2018002175 A PE2018002175 A PE 2018002175A PE 2018002175 A PE2018002175 A PE 2018002175A PE 20190260 A1 PE20190260 A1 PE 20190260A1
Authority
PE
Peru
Prior art keywords
unsubstituted
compound
halide
alkenyl
alkyl
Prior art date
Application number
PE2018002175A
Other languages
English (en)
Spanish (es)
Inventor
Sunil Kumar Kc
Gopi Kumar Mittapalli
Brian Joseph Hofilena
Joseph Timothy Marakovits
Chandramouli Chiruta
Chi Ching Mak
Jianguo Cao
Original Assignee
Samumed Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samumed Llc filed Critical Samumed Llc
Publication of PE20190260A1 publication Critical patent/PE20190260A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/02—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PE2018002175A 2016-04-27 2017-04-27 Isoquinolin-3-il-carboxamidas, y preparacion y uso de las mismas PE20190260A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662328210P 2016-04-27 2016-04-27
PCT/US2017/029797 WO2017189823A2 (en) 2016-04-27 2017-04-27 Isoquinolin-3-yl carboxamides and preparation and use thereof

Publications (1)

Publication Number Publication Date
PE20190260A1 true PE20190260A1 (es) 2019-02-25

Family

ID=60157342

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018002175A PE20190260A1 (es) 2016-04-27 2017-04-27 Isoquinolin-3-il-carboxamidas, y preparacion y uso de las mismas

Country Status (19)

Country Link
US (5) US10508099B2 (enExample)
EP (2) EP3448838B1 (enExample)
JP (1) JP7023243B2 (enExample)
KR (1) KR102399206B1 (enExample)
CN (1) CN109311819B (enExample)
AR (1) AR108326A1 (enExample)
AU (1) AU2017258187B2 (enExample)
BR (1) BR112018072190A2 (enExample)
CA (1) CA3022044A1 (enExample)
CL (2) CL2018003050A1 (enExample)
CO (1) CO2018012655A2 (enExample)
IL (1) IL262495B (enExample)
MA (1) MA43605B1 (enExample)
MX (1) MX386319B (enExample)
PE (1) PE20190260A1 (enExample)
PH (1) PH12018502259A1 (enExample)
RU (1) RU2018141379A (enExample)
SG (2) SG10201914127PA (enExample)
WO (1) WO2017189823A2 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9604930B2 (en) 2012-12-21 2017-03-28 Epizyme, Inc. Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof
AR108326A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
TW201803869A (zh) 2016-04-27 2018-02-01 健生藥品公司 作為RORγT調節劑之6-胺基吡啶-3-基噻唑
AR108325A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
WO2017205536A2 (en) * 2016-05-24 2017-11-30 Genentech, Inc. Therapeutic compounds and uses thereof
MX2019010302A (es) 2017-03-30 2019-11-21 Hoffmann La Roche Isoquinolinas como inhibidores de hpk1.
EP3651762B1 (en) 2017-07-12 2024-07-03 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
WO2019079410A1 (en) * 2017-10-17 2019-04-25 Vanderbilt University ANTAGONISTS OF THE MUSCARINIC RECEPTOR OF ACETYLCHOLINE M4
US10604514B2 (en) * 2017-10-19 2020-03-31 Samumed, Llc 6-(5-membered heteroaryl)isoquinolin-3-yl carboxamides and preparation and use thereof
JP7270989B2 (ja) 2017-10-20 2023-05-11 ヴァンダービルト ユニバーシティー ムスカリン性アセチルコリン受容体m4のアンタゴニスト
US10653688B2 (en) 2017-10-27 2020-05-19 Samumed, Llc 6-(6-membered heteroaryl and aryl)isoquinolin-3-yl carboxamides and preparation and use thereof
US10413537B2 (en) 2017-10-27 2019-09-17 Samumed, Llc 6-(5-membered heteroaryl)isoquinolin-3-yl-(5-membered heteroaryl) carboxamides and preparation and use thereof
US10703748B2 (en) 2017-10-31 2020-07-07 Samumed, Llc Diazanaphthalen-3-yl carboxamides and preparation and use thereof
CN112566901A (zh) 2018-06-18 2021-03-26 詹森药业有限公司 作为RORγt的调节剂的苯基取代的吡唑类
CN112334450A (zh) 2018-06-18 2021-02-05 詹森药业有限公司 作为RORγt的调节剂的苯基和吡啶基取代的咪唑
US10975057B2 (en) 2018-06-18 2021-04-13 Janssen Pharmaceutica Nv 6-aminopyridin-3-yl pyrazoles as modulators of RORgT
US11034658B2 (en) 2018-06-18 2021-06-15 Janssen Pharmaceutica Nv Pyridinyl pyrazoles as modulators of RORγT
JP7386841B2 (ja) 2018-07-24 2023-11-27 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト イソキノリン化合物及びその使用
TW202024053A (zh) * 2018-10-02 2020-07-01 美商建南德克公司 異喹啉化合物及其用途
TW202023558A (zh) 2018-10-03 2020-07-01 美商建南德克公司 8-胺基異喹啉化合物及其用途
WO2021004547A1 (en) * 2019-07-11 2021-01-14 Guangdong Newopp Biopharmaceuticals Co., Ltd. Heterocyclic compounds as inhibitors of hpk1
KR20220058553A (ko) * 2019-09-05 2022-05-09 루난 파마슈티컬 그룹 코퍼레이션 Magl 억제제 및 이의 제조 방법, 용도
WO2021257977A1 (en) * 2020-06-19 2021-12-23 Vanderbilt University Arylsulfonyl derivatives and their use as muscarinic acetylcholine receptor m5 inhibitors
AU2021371136A1 (en) * 2020-10-29 2023-05-11 Merck Sharp & Dohme Llc N-linked isoquinoline amides as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
KR20230157981A (ko) * 2021-02-19 2023-11-17 칼비스타 파마슈티컬즈 리미티드 인자 xiia 저해제
WO2023055679A1 (en) * 2021-10-01 2023-04-06 Merck Sharp & Dohme Llc C-linked isoquinoline amides as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
EP4173673A1 (en) * 2021-10-26 2023-05-03 Perha Pharmaceuticals Imidazolone derivatives as inhibitors of protein kinases in particular dyrk1a, clk1 and/or clk4
AU2022407173A1 (en) * 2021-12-10 2024-06-27 Prothena Biosciences Limited Heterocyclic compounds as dyrk1a inhibitors
TW202506660A (zh) * 2023-04-27 2025-02-16 美商塞普特納公司 Mrgprx2拮抗劑及其使用方法
KR102929140B1 (ko) 2023-05-09 2026-02-24 주식회사 베노바이오 Bet 단백질을 저해하는 신규한 벤조사이오펜 유도체 및 이를 이용한 암 치료용 조성물

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4164559A (en) 1977-09-21 1979-08-14 Cornell Research Foundation, Inc. Collagen drug delivery device
US4474752A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
ES2131463B1 (es) * 1997-04-08 2000-03-01 Lilly Sa Derivados de ciclopropilglicina con propiedades farmaceuticas.
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
US6440102B1 (en) 1998-07-23 2002-08-27 Durect Corporation Fluid transfer and diagnostic system for treating the inner ear
DE19853299C2 (de) 1998-11-19 2003-04-03 Thomas Lenarz Katheter zur Applikation von Medikamenten in Flüssigkeitsräumen des menschlichen Innenohrs
US6120484A (en) 1999-02-17 2000-09-19 Silverstein; Herbert Otological implant for delivery of medicament and method of using same
US6967023B1 (en) 2000-01-10 2005-11-22 Foamix, Ltd. Pharmaceutical and cosmetic carrier or composition for topical application
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
US6648873B2 (en) 2001-09-21 2003-11-18 Durect Corp. Aural catheter system including anchor balloon and balloon inflation device
GB0310867D0 (en) 2003-05-12 2003-06-18 Novartis Ag Organic compounds
US7008953B2 (en) 2003-07-30 2006-03-07 Agouron Pharmaceuticals, Inc. 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
JP2008537684A (ja) 2005-01-24 2008-09-25 ニューロシステック コーポレイション 内耳およびその他の組織へ治療薬および/またはその他の薬剤を送達するための装置および方法
WO2007125405A2 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
CN101821279A (zh) 2007-08-15 2010-09-01 赛特凯恩蒂克公司 某些化学个体、组合物和方法
BR112012002942A2 (pt) * 2009-08-10 2015-10-13 Epitherix Llc indazóis como inibidores da trilha de sinalização de wnt/b-catenina e empregos terapêuticos destes.
ES2835553T3 (es) * 2009-08-10 2021-06-22 Biosplice Therapeutics Inc Inhibidores de indazol de la vía de señalización de Wnt y sus usos terapéuticos
EP2552893B1 (en) * 2010-03-31 2014-10-29 Actelion Pharmaceuticals Ltd. Antibacterial isoquinolin-3-ylurea derivatives
CA2817460A1 (en) 2010-12-17 2012-06-21 F. Hoffmann-La Roche Ag Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof
HUE041576T2 (hu) * 2011-09-14 2019-05-28 Samumed Llc Indazol-3-karboxamid-származékok és alkalmazásuk Wnt/b-katenin szignalizáló útvonal inhibitorokként
WO2013169793A2 (en) * 2012-05-09 2013-11-14 Ipierian, Inc. Methods and compositions for tdp-43 proteinopathies
US9557993B2 (en) 2012-10-23 2017-01-31 Analog Devices Global Processor architecture and method for simplifying programming single instruction, multiple data within a register
BR112016021626A2 (pt) 2014-03-20 2018-05-15 Samumed, Llc indazol-3-carboxamidas 5-substituídas e preparação e uso das mesmas
GB201416754D0 (en) 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
AR108325A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
AR108326A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
US20220062240A1 (en) 2018-06-26 2022-03-03 Biosplice Therapeutics, Inc. Methods of treating cancer using a clk inhibitor

Also Published As

Publication number Publication date
PH12018502259A1 (en) 2019-06-10
CA3022044A1 (en) 2017-11-02
MX2018013173A (es) 2019-02-13
CN109311819A (zh) 2019-02-05
AR108326A1 (es) 2018-08-08
AU2017258187A1 (en) 2018-11-15
JP2019515931A (ja) 2019-06-13
SG11201809310PA (en) 2018-11-29
US20170313681A1 (en) 2017-11-02
US10556885B2 (en) 2020-02-11
BR112018072190A2 (pt) 2019-02-12
IL262495B (en) 2021-12-01
RU2018141379A (ru) 2020-05-28
MA43605A1 (fr) 2020-04-30
SG10201914127PA (en) 2020-02-27
AU2017258187B2 (en) 2021-08-26
US20200339536A1 (en) 2020-10-29
WO2017189823A3 (en) 2018-02-08
EP3448838B1 (en) 2021-08-11
US20180208580A1 (en) 2018-07-26
CO2018012655A2 (es) 2019-04-30
KR20190012167A (ko) 2019-02-08
CN109311819B (zh) 2022-10-25
JP7023243B2 (ja) 2022-02-21
CL2019002067A1 (es) 2020-07-10
US10508099B2 (en) 2019-12-17
EP3448838A4 (en) 2019-12-25
US20230104155A1 (en) 2023-04-06
EP3448838A2 (en) 2019-03-06
US11673881B2 (en) 2023-06-13
MX386319B (es) 2025-03-18
WO2017189823A2 (en) 2017-11-02
EP3943086A1 (en) 2022-01-26
US10287267B2 (en) 2019-05-14
CL2018003050A1 (es) 2019-01-25
KR102399206B1 (ko) 2022-05-17
IL262495A (en) 2018-12-31
US11174244B2 (en) 2021-11-16
MA43605B1 (fr) 2020-10-28
US20180222887A1 (en) 2018-08-09
RU2018141379A3 (enExample) 2020-08-13

Similar Documents

Publication Publication Date Title
AR091247A1 (es) Procesos para producir ciertos 2-(piridin-3-il)tiazoles
PE20160995A1 (es) Inhibidores de syk
AR105774A1 (es) Procedimiento para la preparación de (4s)-4-(4-ciano-2-metoxifenilo)-5-etoxi-2,8-dimetilo-1,4-dihidro-1,6-naftiridina-3-carboxamida y su purificación para su uso como principio activo farmacéutico
AR112774A1 (es) Análogos de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona
EA201690879A1 (ru) Новое триазолопиридиновое соединение
EA201690153A1 (ru) Замещенные бензофуранильные и бензоксазолильные соединения и их применения
AR091246A1 (es) Procesos para producir 2-(piridin-3-il)tiazoles
NZ732649A (en) Picolinamides and related compounds
AR112392A1 (es) Compuesto tricíclico de pirazol, su uso para fabricar un medicamento y composición farmaceutica que lo comprende
PE20142461A1 (es) Moduladores del receptor de estrogeno y sus usos
PE20160523A1 (es) Derivados de arilo o heteroarilo como inhibidores de moleculas pequenas de fibrosis
PE20181288A1 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
MX2016008910A (es) Compuestos de fenil-triazolo-piridina.
AR113296A1 (es) Pirrolidinonas y un proceso para preparar las mismas
CO2018010787A2 (es) Compuesto de griseofulvina
PE20150877A1 (es) Composicion herbicida que tiene actividad herbicida mejorada
AR081725A1 (es) Derivados de oxadiazol, proceso de preparacion de los mismos, composicion farmaceutica que los contienen y su uso en el tratamiento del cancer
CY1117688T1 (el) Ενωσεις τετραϋδροπυρρολοθειαζινης
PE20200387A1 (es) Proceso novedoso para la elaboracion de compuestos para su uso en el tratamiento del cancer
PE20141201A1 (es) Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv)
CY1121626T1 (el) Νεο παραγωγο υδροξαμικου οξεος ή αλας αυτου
EA201691150A1 (ru) Соединения изопропилтриазолопиридина
PE20191488A1 (es) Activador de nrf2
PE20171649A1 (es) ALCOHOLES TRIFLUOROMETILICOS COMO MODULADORES DE ROR(gamma)T
EA201791671A1 (ru) 4-замещенные соединения бензоксаборола и их применение